ARD Retention bonus











































They give retention bonuses because they know they are going to fuck everything up! The only way to keep talent is to hang that bonus in front of them. Why else would they give retention bonuses???
 


















They give retention bonuses because they know they are going to fuck everything up! The only way to keep talent is to hang that bonus in front of them. Why else would they give retention bonuses???

How much was the retention bonus for the Ofirmev reps? Oh yeah, they don't get a fucking thing for Tylenol.
 










































retention bonus or not writing is on the wall, internet, everywhere, check out post on LinkedIn today by
seekingalpha.com
BUSTED, the deceit is catching up with the greedy fuckers that run this company, should be interesting to see how they spin it at meeting, let's ask MT how he plans to spend his multi million bonus
 






You mean this one?

Back in January, Martin Shkreli explained to Benzinga why a Federal Trade Commission lawsuit against the company is justified. Prior to that, notable short-seller Citron Research published a scathing short report against the company.

The Newest Report
On Monday, a Seeking Alpha contributor named "Agloe Capital" published a new short report against Mallinckrodt.

According to Agloe Capital, Mallinckrodt hasn't been transparent with investors. For example, the researcher uncovered evidence across various social media sites that indicates that the price of the company's Acthar therapy was raised by at least 15 percent. This contradicts the company's CEO Mark Trudeau's assertion of a 5 percent annual price hike.

"This alleged price hike is plausible because Mallinckrodt does not disclose the price or volume of Acthar," the report explained. "Mallinckrodt only discloses Acthar net sales. Increases in the net sales could be due to organic growth of Acthar, increase in the price of Acthar, or a mix of both. Because Mallinckrodt does not disclose the price of Acthar and only gives general guidance (e.g., 'price increases on Acthar have averaged in the low-single digits') investors are left to estimate organic growth. If Mallinckrodt did increase the price of Acthar more than investors believed, then their organic growth assumptions will be wrong and the whole Acthar story will need to be re-evaluated."

Agloe Capital also cited other irregularities involving Acthar and other notable events which may not seem like a concern on its own, such as a defunct webpage for a program which appears to still be running yet not disclosed in any SEC filings. However, given the viewpoint that management needs to be more open and transparent with investors it certainly merits an explanation from management.
 






Doesn't matter how he spins it! There is too much smoke for there not to be a fire. Sooner or later someone will start spilling their guts, securities fraud is a big no-no! Jail time!